0001683168-26-003684
SEC filingActuate Therapeutics announces FDA clearance of IND for Phase 1/2 study of oral elraglusib in advanced solid tumors and appoints Martin Huber, MD to its Board of Directors.
Actuate Therapeutics' receipt of FDA IND clearance marks a pivotal advancement for its lead asset elraglusib, transitioning from IV to oral tablet formulation to improve patient convenience, pharmacokinetic exposure, and broader clinical utility across multiple high-unmet-need oncology indications. This is underpinned by Phase 2 data in metastatic pancreatic ductal adenocarcinoma demonstrating a direct link between higher drug exposure and improved overall survival, with oral dosing projected to achieve target levels more consistently and enable daily administration versus weekly IV. The planned Phase 1/2 trial in 2H 2026 will focus on safety, dosing, and early efficacy signals in metastatic melanoma, NSCLC, colorectal, and pancreatic cancers, positioning elraglusib for potential expansion into blockbuster markets. Parallel efforts include preclinical synergy data with RAS inhibitors due mid-2026 and regulatory discussions with FDA and EMA for pivotal trial designs. The appointment of Martin Huber, MD—an industry veteran with leadership at Mersana Therapeutics and board experience at Syndax—to the Board enhances execution capabilities amid these milestones, particularly in advancing the oral program and pediatric indications in Ewing sarcoma and neuroblastoma.